Hong Kong Stock Movement
XUANZHUBIO-B fell by 10.19%. Based on recent news,
<ol>
<li>
On December 12, XUANZHUBIO's two new cancer drugs were approved. Despite the products having high intracranial penetration and differentiated indications, the market remains skeptical about their commercialization prospects, leading to a decline in stock price. The market penetration of Diroxalic and Pirarubicin did not immediately translate into stock price support, affecting investor confidence.
</li>
<li>
On December 12, in the context of the pharmaceutical industry's return to product value, XUANZHUBIO's innovative value realization did not immediately reflect in the stock price, and the market holds a wait-and-see attitude towards its long-term growth potential, putting pressure on the stock price.
</li>
<li>
No other significant news recently. Increased competition in the pharmaceutical industry and volatility in the innovative drug market.
</li>
</ol>
Stocks with High Trading Volume in the Industry
Shijiazhuang Pharmaceutical Group fell by 2.74%. Based on recent key news:
<ol>
<li>
On December 15, Shijiazhuang Pharmaceutical Group announced that its developed Liposomal Irinotecan Hydrochloride Injection for a new indication has been approved by the National Medical Products Administration for first-line treatment of metastatic pancreatic cancer patients. This approval could have a positive impact on the stock price, but the market reaction was below expectations, leading to a decline in stock price.
</li>
<li>
On December 12, the biopharmaceutical subsidiary of Shijiazhuang Pharmaceutical Group applied for a listing in Hong Kong, planning to alleviate financial pressure through external financing to support the development of innovative drug business. Although this news shows the company's efforts to expand financing channels, the market remains concerned about its short-term financial pressure, affecting stock performance.
</li>
<li>
On December 12, Shijiazhuang's innovative R&amp;D expenses soared to 530 million yuan, a year-on-year increase of 42.7%, while the revenue from the innovative drug business accounted for only 9.5% of total revenue. The high R&amp;D investment and low income ratio raised market concerns about the company's profitability, putting pressure on the stock price. In the era of pharmaceutical innovation 2.0, industry competition is intensifying.
</li>
</ol>
China Biologic Products fell by 3.68%. Based on recent key news:
<ol>
<li>
On December 12, China Biologic Products announced that its independently developed innovative drug Kemosir Capsule has received market approval from the National Medical Products Administration of China. This drug is used for the treatment of hormone receptor-positive, HER2-negative breast cancer patients, showing significant efficacy and safety. This news had a positive impact on the stock price, but the market reaction was below expectations, leading to a decline in stock price.
</li>
<li>
On December 11, Kemosir Capsule, as the world's first CDK2/4/6 inhibitor, demonstrated significant effects in prolonging progression-free survival and reducing the risk of disease progression or death. Despite the drug's approval, the market remains cautious about its future sales performance, affecting the stock price.
</li>
<li>
On December 12, the clinical trial results of Kemosir Capsule showed a significant increase in objective response rate and good safety. However, the market still has doubts about its long-term market potential, leading to pressure on the stock price. The Hong Kong stock market has recently experienced increased volatility, requiring attention to policy changes.
</li>
</ol>
Hansoh Pharmaceutical fell by 8.65%. Based on recent news,
<ol>
<li>
On December 12, Hansoh Pharmaceutical's stock price broke above the 5-day moving average, indicating technical buying in the short term. However, the stock price subsequently fell sharply, with a decline of 8.65%
</li>
<li>
On December 3rd, HSBC released a report maintaining a buy rating for Hansoh Pharmaceutical, with a target price of HKD 47. Despite the positive rating, it failed to prevent the stock price from falling.
</li>
<li>
Recently, the overall sentiment in the pharmaceutical industry has been cautious, with investors adopting a wait-and-see attitude towards future earnings expectations, leading to pressure on Hansoh Pharmaceutical's stock price. The overall sentiment in the pharmaceutical industry is cautious, with investors on the sidelines.
</li>
</ol>
Stocks ranked among the top in industry market capitalization
Hengrui Medicine fell by 0.76%. Based on recent key news:
<ol>
<li>
On December 12th, Hengrui Medicine's subsidiary Fujian Shengdi Pharmaceutical received a clinical trial notification for HRS9531 injection from the National Medical Products Administration. This drug targets metabolic dysfunction-related fatty liver disease and has global independent intellectual property rights, expected to improve liver lipid accumulation and inflammatory response. This news drove stock price fluctuations.
</li>
<li>
On December 12th, Hengrui Medicine's subsidiary Suzhou Shengdiya Biopharmaceutical obtained clinical trial approval for SHR-A1811(sc) injection. This drug induces apoptosis in tumor cells by binding to HER2-expressing tumor cells and releasing toxins, enhancing anti-tumor efficacy. This news impacted the stock price.
</li>
<li>
On December 15th, Hengrui Medicine announced that four products received clinical trial approvals, with a cumulative R&amp;D investment of approximately 2.23 billion yuan. This news demonstrates the company's positive progress in R&amp;D, affecting market sentiment. The pharmaceutical industry's R&amp;D investment is increasing, and market competition is intense
</li>
</ol>

02575

XUANZHUBIO-B fell 10.19%; CSPC Pharmaceutical Group fell 2.74%, with a transaction volume of HKD 470 million; China Biologic Products fell 3.68%, with a transaction volume of HKD 294 million; Hansoh Pharmaceutical fell 8.65%, with a transaction volume of HKD 280 million; Heng Rui Medicine fell 0.76%, with a market value of HKD 477.5 billion

Hong Kong Stock Movement: Approval of new cancer drug fails to alleviate market concerns, XUANZHUBIO's stock price plummets 10.19%